Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics

References

• MeltzerHYTreatment-resistant schizophrenia–the role of clozapineCurr Med Res Opin19971411209524789
   PubMed Web of Science ®Google Scholar
• NICEPsychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178)LondonRoyal College of Psychiatrists2014
   Google Scholar
• LiebermanJAPhillipsMGuHAtypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazineNeuropsychopharmacology2003285995100312700715
   PubMed Web of Science ®Google Scholar
• GirgisRRPhillipsMRLiXClozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trialBr J Psychiatry2011199428128821292928
   PubMed Web of Science ®Google Scholar
• DemjahaAMurrayRMMcGuirePKKapurSHowesODDopamine synthesis capacity in patients with treatment-resistant schizophreniaAm J Psychiatry2012169111203121023034655
   PubMed Web of Science ®Google Scholar
• DemjahaAEgertonAMurrayRMAntipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine functionBiol Psychiatry2014755e11e1323890739
   PubMed Web of Science ®Google Scholar
• ChakosMLiebermanJHoffmanEBradfordDSheitmanBEffectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trialsAm J Psychiatry2001158451852611282684
   PubMed Web of Science ®Google Scholar
• WahlbeckKCheineMEssaliAAdamsCEvidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trialsAm J Psychiatry1999156799099910401441
   PubMed Web of Science ®Google Scholar
• MeltzerHYTreatment of the neuroleptic-nonresponsive schizophrenic patientSchizophr Bull19921835155421357741
   PubMed Web of Science ®Google Scholar
• DownsJMZinklerMClozapine: national review of postcode prescribingPsychiatrist20073110384387
   Google Scholar
• NielsenJRogeRSchjerningOSorensenHJTaylorDGeographical and temporal variations in clozapine prescription for schizophreniaEur Neuropsychopharmacol2012221181882422503785
   PubMed Web of Science ®Google Scholar
• StroupTSGerhardTCrystalSHuangCOlfsonMGeographic and clinical variation in clozapine use in the United StatesPsychiatr Serv201465218619224233347
   PubMed Web of Science ®Google Scholar
• HowesODVergunstFGeeSMcGuirePKapurSTaylorDAdherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiationBr J Psychiatry2012201648148522955007
   PubMed Web of Science ®Google Scholar
• HayesRDDownsJChangCKThe effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confoundersSchizophr Bull201541364465525154620
   PubMed Web of Science ®Google Scholar
• TiihonenJLonnqvistJWahlbeckK11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)Lancet2009374969062062719595447
   PubMed Web of Science ®Google Scholar
• LallyJTullyJRobertsonDStubbsBGaughranFMacCabeJHAugmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysisSchizophr Res20161711–321522426827129
   PubMed Web of Science ®Google Scholar
• MustafaFABurkeJGAbukmeilSSScanlonJJCoxM“Schizophrenia past Clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribingPharmacopsychiatry2015481111425376977
   PubMed Web of Science ®Google Scholar
• DavisMCFullerMAStraussMEKonickiPEJaskiwGEDiscontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patientsActa Psychiatr Scand20141301303924299466
   PubMed Web of Science ®Google Scholar
• FaulknerEAnnemansLGarrisonLChallenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest groupValue Health20121581162117123244820
   PubMed Web of Science ®Google Scholar
• RellingMVEvansWEPharmacogenomics in the clinicNature2015526757334335026469045
   PubMed Web of Science ®Google Scholar
• FeinbergAPFallinMDEpigenetics at the crossroads of genes and the environmentJAMA2015314111129113026372577
   PubMed Web of Science ®Google Scholar
• BirdAPerceptions of epigeneticsNature2007447714339639817522671
   PubMed Web of Science ®Google Scholar
• ReesEO’DonovanMCOwenMJGenetics of schizophreniaCurr Opin Behav Sci20152814
   Google Scholar
• RuderferDMCharneyAWReadheadBPolygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approachLancet Psychiatry20163435035726915512
   PubMed Web of Science ®Google Scholar
• GressierFPorcelliSCalatiRSerrettiAPharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysisEur Neuropsychopharmacol201626216318526792444
   PubMed Web of Science ®Google Scholar
• KohlrauschFBPharmacogenetics in schizophrenia: a review of clozapine studiesRev Bras Psiquiatr201335330531724142094
   PubMed Web of Science ®Google Scholar
• SriretnakumarVHuangEMullerDJPharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an updateExpert Opin Drug Metab Toxicol201511111709173126364648
   PubMed Web of Science ®Google Scholar
• ZhangJPMalhotraAKPharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionExpert Opin Drug Metab Toxicol20117193721162693
   PubMed Web of Science ®Google Scholar
• IyegbeCCampbellDButlerAAjnakinaOShamPThe emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE researchSoc Psychiatry Psychiatr Epidemiol201449216918224435092
   PubMed Web of Science ®Google Scholar
• HwangRZaiCTiwariAEffect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variantPharmacogenomics J201010320021820029384
   PubMed Web of Science ®Google Scholar
• ScharfetterJChaudhryHRHornikKDopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patientsEur Neuropsychopharmacol1999101172010647091
   PubMed Web of Science ®Google Scholar
• ShaikhSCollierDAShamPCAllelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophreniaHum Genet19969767147198641685
   PubMed Web of Science ®Google Scholar
• XuMXingQLiSPharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20103461026103220580759
   PubMed Web of Science ®Google Scholar
• ArranzMCollierDSodhiMAssociation between clozapine response and allelic variation in 5-HT2A receptor geneLancet199534689702812827630250
   PubMed Web of Science ®Google Scholar
• ArranzMJMunroJOwenMJEvidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapineMol Psychiatry19983161669491814
   PubMed Web of Science ®Google Scholar
• ArranzMJMunroJBirkettJPharmacogenetic prediction of clozapine responseLancet200035592151615161610821369
   PubMed Web of Science ®Google Scholar
• YuYWTsaiSJLinCHHsuCPYangKHHongCJSerotonin-6 receptor variant (C267T) and clinical response to clozapineNeuroreport19991061231123310363930
   PubMed Web of Science ®Google Scholar
• SchumacherJSchulzeTGWienkerTFRietschelMNothenMMPharmacogenetics of the clozapine responseLancet20003569228506507
   PubMed Web of Science ®Google Scholar
• ArranzMJMunroJOsborneSCollierDKerwinRWDifficulties in replication of resultsLancet2000356923813591360
   PubMed Web of Science ®Google Scholar
• ArranzMJde LeonJPharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of researchMol Psychiatry200712870774717549063
   PubMed Web of Science ®Google Scholar
• BellRMcLarenAGalanosJCopolovDThe clinical use of plasma clozapine levelsAust N Z J Psychiatry19983245675749711372
   PubMed Web of Science ®Google Scholar
• KronigMHMunneRASzymanskiSPlasma clozapine levels and clinical response for treatment-refractory schizophrenic patientsAm J Psychiatry199515221791827840349
   PubMed Web of Science ®Google Scholar
• CooperTBClozapine plasma level monitoring: current statusPsychiatr Q19966742973118938830
   PubMed Web of Science ®Google Scholar
• MillerDDFlemingFHolmanTLPerryPJPlasma clozapine concentrations as a predictor of clinical response: a follow-up studyJ Clin Psychiatry199455Suppl B1171217961554
   PubMed Web of Science ®Google Scholar
• SpinaEAvenosoAFacciolaGRelationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neurolepticsPsychopharmacology (Berl)20001481838910663421
   PubMed Web of Science ®Google Scholar
• EapCBBenderSJaquenoud SirotENonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 geneJ Clin Psychopharmacol200424221421915206669
   PubMed Web of Science ®Google Scholar
• OzdemirVKalowWOkeyABTreatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamineJ Clin Psychopharmacol200121660360711763009
   PubMed Web of Science ®Google Scholar
• BalibeyHBasogluCLundgrenSCYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophreniaKlin Psikofarmakol B20112129399 Turkish
   Google Scholar
• Kootstra-RosJESmallegoorWvan der WeideJThe cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patientsAnn Clin Biochem200542Pt 321621915949157
   PubMed Web of Science ®Google Scholar
• de BritoRBde Carvalho AraújoLDinizMJThe CYP1A2-163C>A polymorphism is associated with super-refractory schizophreniaSchizophr Res20151691–350250326530626
   PubMed Web of Science ®Google Scholar
• LeeSTRyuSKimSRAssociation study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment responseJ Clin Psychopharmacol201232444144822722500
   PubMed Web of Science ®Google Scholar
• RajkumarAPPoonkuzhaliBKuruvillaASrivastavaAJacobMJacobKSAssociation between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophreniaActa Neuropsychiatr201325121126953068
   PubMed Web of Science ®Google Scholar
• LuMLLaneHYChenKPJannMWSuMHChangWHFluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patientsJ Clin Psychiatry200061859459910982203
   PubMedGoogle Scholar
• Rostami-HodjeganAAminAMSpencerEPLennardMSTuckerGTFlanaganRJInfluence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patientsJ Clin Psychopharmacol2004241707814709950
   PubMed Web of Science ®Google Scholar
• DobrinasMCornuzJOnedaBKohler SerraMPuhlMEapCBImpact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibilityClin Pharmacol Ther201190111712521593735
   PubMed Web of Science ®Google Scholar
• KrivoyAGaughranFWeizmanABreenGMacCabeJHGene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic reviewInt Clin Psychopharmacol201631417918425563806
   PubMed Web of Science ®Google Scholar
• MegaJLWalkerJRRuffCTGenetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trialLancet201538599842280228725769357
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUGlutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicalityProg Neuropsychopharmacol Biol Psychiatry20032771113112314642971
   PubMed Web of Science ®Google Scholar
• HowesOMcCutcheonRStoneJGlutamate and dopamine in schizophrenia: an update for the 21st centuryJ Psychopharmacol20152929711525586400
   PubMed Web of Science ®Google Scholar
• EvinsAEAmicoETShihVGoffDCClozapine treatment increases serum glutamate and aspartate compared to conventional neurolepticsJ Neural Transm (Vienna)19971046–77617669444574
   PubMed Web of Science ®Google Scholar
• MeshulCKBunkerGLMasonJNAllenCJanowskyAEffects of subchronic clozapine and haloperidol on striatal glutamatergic synapsesJ Neurochem1996675196519738863502
   PubMed Web of Science ®Google Scholar
• PilowskyLSBressanRAStoneJMFirst in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patientsMol Psychiatry200611211811916189506
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomics ConsortiumBiological insights from 108 schizophrenia-associated genetic lociNature2014511751042142725056061
   PubMed Web of Science ®Google Scholar
• KirovGPocklingtonAJHolmansPDe novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophreniaMol Psychiatry201217214215322083728
   PubMed Web of Science ®Google Scholar
• TaylorDLTiwariAKLiebermanJAGenetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapineHum Psychopharmacol201631212113426876050
   PubMed Web of Science ®Google Scholar
• NielsenJDahmMLublinHTaylorDPsychiatrists’ attitude towards and knowledge of clozapine treatmentJ Psychopharmacol201024796597119164499
   PubMed Web of Science ®Google Scholar
• AlvirJMLiebermanJASaffermanAZSchwimmerJLSchaafJAClozapine-induced agranulocytosis. Incidence and risk factors in the United StatesN Engl J Med199332931621678515788
   PubMed Web of Science ®Google Scholar
• AtkinKKendallFGouldDFreemanHLibermanJO’SullivanDNeutropenia and agranulocytosis in patients receiving clozapine in the UK and IrelandBr J Psychiatry199616944834888894200
   PubMed Web of Science ®Google Scholar
• GoldsteinJIJarskogLFHilliardCClozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B allelesNat Commun20145475725187353
   PubMed Web of Science ®Google Scholar
• AthanasiouMCDettlingMCascorbiICandidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosisJ Clin Psychiatry201172445846320868635
   PubMed Web of Science ®Google Scholar
• ChowdhuryNIRemingtonGKennedyJLGenetics of antipsychotic-induced side effects and agranulocytosisCurr Psychiatry Rep201113215616521336863
   PubMed Web of Science ®Google Scholar
• VerbelenMCollierDACohenDMacCabeJHLewisCMEstablishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosisPharmacogenomics J201515546146625732907
   PubMed Web of Science ®Google Scholar
• CentorrinoFBaldessariniRJFloodJGKandoJCFrankenburgFRRelation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolitesAm J Psychiatry199515246106127694912
   PubMed Web of Science ®Google Scholar
• HasegawaMColaPAMeltzerHYPlasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosisNeuropsychopharmacology199411145477945743
   PubMed Web of Science ®Google Scholar
• LeggeSEHamshereMLRipkeSClozapine-Induced Agranulocytosis, Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropeniaMol Psychiatry20168910.1038/mp.2016.137
   Web of Science ®Google Scholar
• SaitoTIkedaMMushirodaTPharmacogenomic study of clozapine-induced agranulocytosis/granulocytopenia in a Japanese populationBiol Psychiatry Epub2016211
   Web of Science ®Google Scholar
• YunisJJCorzoDSalazarMLiebermanJAHowardAYunisEJHLA associations in clozapine-induced agranulocytosisBlood1995863117711837620171
   PubMed Web of Science ®Google Scholar
• DettlingMSchaubRTMueller-OerlinghausenBRootsICascorbiIFurther evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestryPharmacogenetics200111213514111266078
   PubMedGoogle Scholar
• VancampfortDStubbsBMitchellAJRisk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysisWorld Psychiatry201514333934726407790
   PubMed Web of Science ®Google Scholar
• VancampfortDCorrellCUGallingBDiabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysisWorld Psychiatry201615216617427265707
   PubMed Web of Science ®Google Scholar
• Gardner-SoodPLallyJSmithSCardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trialPsychol Med201545122619262925961431
   PubMed Web of Science ®Google Scholar
• MitchellAJVancampfortDSweersKvan WinkelRYuWDe HertMPrevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysisSchizophr Bull201339230631822207632
   PubMed Web of Science ®Google Scholar
• SahaSChantDMcGrathJA systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?Arch Gen Psychiatry200764101123113117909124
   PubMed Web of Science ®Google Scholar
• ChangCKHayesRDPereraGLife expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in LondonPLoS One201165e1959021611123
   PubMed Web of Science ®Google Scholar
• HendersonDCCaglieroEGrayCClozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic studyAm J Psychiatry2000157697598110831479
   PubMed Web of Science ®Google Scholar
• BakMFransenAJanssenJvan OsJDrukkerMAlmost all antipsychotics result in weight gain: a meta-analysisPLoS One201494e9411224763306
   PubMed Web of Science ®Google Scholar
• LambertiJSBellnierTSchwarzkopfSBWeight gain among schizophrenic patients treated with clozapineAm J Psychiatry199214956896901349460
   PubMed Web of Science ®Google Scholar
• AllisonDBMentoreJLHeoMAntipsychotic-induced weight gain: a comprehensive research synthesisAm J Psychiatry1999156111686169610553730
   PubMed Web of Science ®Google Scholar
• ArranzMJRiveraMMunroJCPharmacogenetics of response to antipsychotics in patients with schizophreniaCNS Drugs2011251193396922054119
   PubMed Web of Science ®Google Scholar
• RajaMRajaSClozapine safety, 40 years laterCurr Drug Saf20149316319524809463
   PubMedGoogle Scholar
• WallaceTJZaiCCBrandlEJMullerDJRole of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gainPharmacogenomics Pers Med201148393
   Google Scholar
• GunesAMelkerssonKIScordoMGDahlMLAssociation between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapineJ Clin Psychopharmacol2009291656819142110
   PubMed Web of Science ®Google Scholar
• MillerDDEllingrodVLHolmanTLBuckleyPFArndtSClozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphismAm J Med Genet B Neuropsychiatr Genet2005133B19710015635667
   PubMed Web of Science ®Google Scholar
• ReynoldsGPZhangZZhangXPolymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gainAm J Psychiatry2003160467767912668355
   PubMed Web of Science ®Google Scholar
• De LucaVMullerDJHwangRHTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysisHum Psychopharmacol200722746346717702092
   PubMed Web of Science ®Google Scholar
• TsaiSJHongCJYuYWLinCH-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gainLancet200236093471790
   PubMed Web of Science ®Google Scholar
• TheisenFMHinneyABromelTLack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individualsPsychiatr Genet200414313914215318026
   PubMed Web of Science ®Google Scholar
• BrandlEJFrydrychowiczCTiwariAKAssociation study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gainProg Neuropsychopharmacol Biol Psychiatry201238213414122426215
   PubMed Web of Science ®Google Scholar
• KangSHLeeJIHanHRSohMHongJPPolymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophreniaPsychiatr Genet201424624925625304226
   PubMed Web of Science ®Google Scholar
• YevtushenkoOOCooperSJO’NeillRDohertyJKWoodsideJVReynoldsGPInfluence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophreniaBr J Psychiatry2008192642442818515891
   PubMed Web of Science ®Google Scholar
• WangYCBaiYMChenJYLinCCLaiICLiouYJGenetic association between TNF-α −308 G>A polymorphism and longitudinal weight change during clozapine treatmentHum Psychopharmacol201025430330920521320
   PubMed Web of Science ®Google Scholar
• TiwariAKZaiCCLikhodiOA common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in SchizophreniaNeuropsychopharmacology20103561315132420107430
   PubMed Web of Science ®Google Scholar
• ReynoldsGPPharmacogenetic aspects of antipsychotic drug-induced weight gain - a critical reviewClin Psychopharmacol Neurosci2012102717723431082
   PubMedGoogle Scholar
• WangYCBaiYMChenJYLinCCLaiICLiouYJPolymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gainJ Neural Transm (Vienna)2005112111463146815795790
   PubMed Web of Science ®Google Scholar
• CzerwenskyFLeuchtSSteimerWMC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?Int J Neuropsychopharmacol20131692103210923920449
   PubMed Web of Science ®Google Scholar
• ChowdhuryNITiwariAKSouzaRPGenetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor genePharmacogenomics J201313327227922310352
   PubMed Web of Science ®Google Scholar
• ZaiGCZaiCCChowdhuryNIThe role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gainProg Neuropsychopharmacol Biol Psychiatry20123919610122642961
   PubMed Web of Science ®Google Scholar
• MulderHFrankeBvan der-Beek van derAAThe association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophreniaJ Clin Psychopharmacol200727433834317632216
   PubMed Web of Science ®Google Scholar
• MulderHCohenDSchefferHHTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication studyJ Clin Psychopharmacol2009291162019142101
   PubMed Web of Science ®Google Scholar
• BaiYMChenTTLiouYJHongCJTsaiSJAssociation between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychoticsSchizophr Res20111252–317918621185157
   PubMed Web of Science ®Google Scholar
• RisseladaAJVehofJBruggemanRAssociation between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication studyPharmacogenomics J2012121626720680028
   PubMed Web of Science ®Google Scholar
• LiouYJBaiYMLinEGene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychoticsPharmacogenomics J2012121546120877301
   PubMed Web of Science ®Google Scholar
• LiouYJTsaiSJWangYCBaiYMHongCJGenetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychoticsJ Clin Psychopharmacol201333331331823609384
   PubMed Web of Science ®Google Scholar
• van WinkelRRuttenBPPeerboomsOPeuskensJvan OsJDe HertMMTHFR and risk of metabolic syndrome in patients with schizophreniaSchizophr Res20101211–319319820547447
   PubMed Web of Science ®Google Scholar
• AdkinsDEÅbergKMcClayJLGenomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsMol Psychiatry201116332133220195266
   PubMed Web of Science ®Google Scholar
• SmithRCSegmanRHGolcer-DubnerTPavlovVLererBAllelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophreniaPharmacogenomics J20088322823617726453
   PubMed Web of Science ®Google Scholar
• LallyJMacCabeJHPersonalised approaches to pharmacotherapy for schizophreniaAdv Psychiatr Treat20162227886
   Google Scholar
• PotkinSGBasileVSJinYD1 receptor alleles predict PET metabolic correlates of clinical response to clozapineMol Psychiatry20038110911312556915
   PubMed Web of Science ®Google Scholar
• HwangRShinkaiTDe LucaVAssociation study of four dopamine D1 receptor gene polymorphisms and clozapine treatment responseJ Psychopharmacol200721771872717092969
   PubMed Web of Science ®Google Scholar
• HwangRShinkaiTDe LucaVAssociation study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populationsPsychopharmacology (Berl)2005181117918715830237
   PubMed Web of Science ®Google Scholar
• SzekeresGKeriSJuhaszARole of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophreniaAm J Med Genet B Neuropsychiatr Genet2004124B11514681904
   PubMed Web of Science ®Google Scholar
• HwangRShinkaiTDelucaVDopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatmentEur Neuropsychopharmacol200616424825916278074
   PubMed Web of Science ®Google Scholar
• MalhotraAKGoldmanDBuchananRWThe dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine responseMol Psychiatry19983172759491816
   PubMed Web of Science ®Google Scholar
• MasellisMBasileVMeltzerHYSerotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patientsNeuropsychopharmacology19981921231329629566
   PubMed Web of Science ®Google Scholar
• ArranzMJCollierDAMunroJAnalysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapineNeurosci Lett19962172–31771788916101
   PubMed Web of Science ®Google Scholar
• SodhiMSArranzMJCurtisDAssociation between clozapine response and allelic variation in the 5-HT2C receptor geneNeuroreport1995711691728742444
   PubMed Web of Science ®Google Scholar
• MalhotraAKGoldmanDOzakiNBreierABuchananRPickarDLack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapineAm J Psychiatry19961538109210948678181
   PubMed Web of Science ®Google Scholar
• HamdaniNBonniereMAdesJHamonMBoniCGorwoodPNegative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychoticsNeurosci Lett20053771697415722190
   PubMed Web of Science ®Google Scholar
• NothenMMRietschelMErdmannJGenetic variation of the 5-HT2A receptor and response to clozapineLancet19953468979908909
   Web of Science ®Google Scholar
• MalhotraAKGoldmanDOzakiNClozapine response and the 5HT2C Cys23Ser polymorphismNeuroreport1996713210021028930967
   PubMed Web of Science ®Google Scholar
• MasellisMBasileVSMeltzerHYLack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophreniaSchizophr Res2001471495811163544
   PubMed Web of Science ®Google Scholar
• Opgen-RheinCBrandlEJMullerDJAssociation of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German samplePharmacogenomics201011677378020504252
   PubMed Web of Science ®Google Scholar
• CzerwenskyFLeuchtSSteimerWAssociation of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gainJ Clin Psychopharmacol2013331747923277235
   PubMed Web of Science ®Google Scholar
• Lubrano-BerthelierCDubernBLacorteJMMelanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eatingJ Clin Endocrinol Metab20069151811181816507637
   PubMed Web of Science ®Google Scholar
• HongCJLiouYJBaiYMChenTTWangYCTsaiSJDopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatmentPharmacogenet Genomics201020635936620375926
   PubMed Web of Science ®Google Scholar
• HuangHHWangYCWuCLTNF-alpha -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatmentNeurosci Lett2011504327728021967963
   PubMed Web of Science ®Google Scholar
• ReichenbergAMillJMacCabeJHEpigenetics, genomic mutations and cognitive functionCogn Neuropsychiatry2009144–537739019634036
   PubMedGoogle Scholar
• BoksMPde JongNMKasMJCurrent status and future prospects for epigenetic psychopharmacologyEpigenetics201271202822207355
   PubMed Web of Science ®Google Scholar
• PetronisAThe origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesisBiol Psychiatry2004551096597015121478
   PubMed Web of Science ®Google Scholar
• MillJTangTKaminskyZEpigenomic profiling reveals DNA-methylation changes associated with major psychosisAm J Hum Genet200882369671118319075
   PubMed Web of Science ®Google Scholar
• GuidottiAAutaJChenYEpigenetic GABAergic targets in schizophrenia and bipolar disorderNeuropharmacology2011607–81007101621074545
   PubMed Web of Science ®Google Scholar
• MatriscianoFDongEGavinDPNicolettiFGuidottiAActivation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brainMol Pharmacol201180117418221505039
   PubMed Web of Science ®Google Scholar
• HuangHSMatevossianAWhittleCPrefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promotersJ Neurosci20072742112541126217942719
   PubMed Web of Science ®Google Scholar
• DongENelsonMGraysonDRCostaEGuidottiAClozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylationProc Natl Acad Sci USA200810536136141361918757738
   PubMed Web of Science ®Google Scholar
• HowesODKapurSA neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)Br J Psychiatry201420511324986384
   PubMed Web of Science ®Google Scholar
• LallyJAjnakinaODi FortiMTwo Distinct Patterns of Treatment Resistance: Clinical Predictors of Treatment Resistance in First-Episode Schizophrenia Spectrum PsychosesPsychol Med201611010.1017/s0033291716002014
   Web of Science ®Google Scholar
• SchennachRRiedelMMusilRMollerHJTreatment response in first-episode schizophreniaClin Psychopharmacol Neurosci2012102788723430971
   PubMedGoogle Scholar
• HassanANDe LucaVThe effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patientsSchizophr Res20151612–349650025468176
   PubMed Web of Science ®Google Scholar
• FrankJLangMWittSHIdentification of increased genetic risk scores for schizophrenia in treatment-resistant patientsMol Psychiatry201520215015124888364
   PubMed Web of Science ®Google Scholar
• WimberleyTStøvringHSørensenHJHorsdalHTMacCabeJHGasseCPredictors of treatment resistance in patients with schizophrenia: a population-based cohort studyLancet Psychiatry20163435836626922475
   PubMed Web of Science ®Google Scholar
• VanelleJMTreatment refractory schizophreniaEncephale19952131321 French
   Google Scholar
• MeltzerHYRabinowitzJLeeMAAge at onset and gender of schizophrenic patients in relation to neuroleptic resistanceAm J Psychiatry199715444754829090333
   PubMed Web of Science ®Google Scholar
• MartinAKMowryBIncreased rare duplication burden genomewide in patients with treatment-resistant schizophreniaPsychol Med201646346947626349998
   PubMed Web of Science ®Google Scholar
• LiebermanJASaffermanAZPollackSClinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcomeAm J Psychiatry199415112174417527977880
   PubMed Web of Science ®Google Scholar
• SemizUBCetinMBasogluCClinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophreniaProg Neuropsychopharmacol Biol Psychiatry20073161330133617618026
   PubMed Web of Science ®Google Scholar
• PickarDOwenRRJrLitmanREHsiaoJKSuTPPredictors of clozapine response in schizophreniaJ Clin Psychiatry199455append B1291327525541
   PubMed Web of Science ®Google Scholar
• RosenheckRLawsonWCraytonJPredictors of differential response to clozapine and haloperidol. Veterans Affairs Cooperative Study Group on Clozapine in Refractory SchizophreniaBiol Psychiatry19984464754829777179
   PubMed Web of Science ®Google Scholar
• UmbrichtDSWirshingWCWirshingDAClinical predictors of response to clozapine treatment in ambulatory patients with schizophreniaJ Clin Psychiatry200263542042412019667
   PubMed Web of Science ®Google Scholar
• UcokACikrikciliUKarabulutSDelayed initiation of clozapine may be related to poor response in treatment-resistant schizophreniaInt Clin Psychopharmacol201530529029526163875
   PubMed Web of Science ®Google Scholar
• NielsenJNielsenRECorrellCUPredictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register StudyJ Clin Psychopharmacol201232567868322926603
   PubMed Web of Science ®Google Scholar
• IkedaMYoshimuraRHashimotoRGenetic overlap between antipsychotic response and susceptibility to schizophreniaJ Clin Psychopharmacol2015351858825502484
   PubMed Web of Science ®Google Scholar
• HettigeNCColeCBKhalidSDe LucaVPolygenic risk score prediction of antipsychotic dosage in schizophreniaSchizophr Res20161702–326527026778674
   PubMed Web of Science ®Google Scholar
• MalhotraAKCorrellCUChowdhuryNIAssociation between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gainArch Gen Psychiatry201269990491222566560
   PubMed Web of Science ®Google Scholar
• JamesonJLLongoDLPrecision medicine -- personalized, problematic, and promisingN Engl J Med2015372232229223426014593
   PubMed Web of Science ®Google Scholar
• JoynerMJPanethNSeven questions for personalized medicineJAMA201531410999100026098474
   PubMed Web of Science ®Google Scholar
• ShabaruddinFHFleemanNDPayneKEconomic evaluations of personalized medicine: existing challenges and current developmentsPharmacogenomics Pers Med20158115126
   PubMed Web of Science ®Google Scholar
• EversKPersonalized medicine in psychiatry: ethical challenges and opportunitiesDialogues Clin Neurosci200911442743420135900
   PubMedGoogle Scholar
• StanekEJSandersCLTaberKAAdoption of pharmacogenomic testing by US physicians: results of a nationwide surveyClin Pharmacol Ther201291345045822278335
   PubMed Web of Science ®Google Scholar
• MalhotraAKZhangJPLenczTPharmacogenetics in psychiatry: translating research into clinical practiceMol Psychiatry201217876076922083729
   PubMed Web of Science ®Google Scholar
• HoopJGLapidMIPaulsonRMRobertsLWClinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 “early adopting” departments of psychiatryJ Clin Psychiatry201071674575320361898
   PubMed Web of Science ®Google Scholar
• CrewsKRHicksJKPuiCHRellingMVEvansWEPharmacogenomics and individualized medicine: translating science into practiceClin Pharmacol Ther201292446747522948889
   PubMed Web of Science ®Google Scholar